


# CERTIFICATE OF ANALYSIS No.: 2022-10264

## CLIENT

KANNABIO HEMP HELLAS, SKOUFA 110  
38334 VOLOS, Greece

## SAMPLE \*

CARE DROPS 5%



Sample condition: SUITABLE  
Sample ID: 2242004  
Sample type: Viscous liquid  
Batch No.: \* 42600

Work order: 2022-107003  
Analysis ID: 2022\_244  
Method ID: PHL\_RPC\_12C  
Method SOP: MET-LAB-003-02

Sample received: 17/10/2022  
Start of analysis: 26/10/2022  
End of analysis: 28/10/2022  
Analyst: Blaž Janežič

\* Information provided by the client.

## CANNABINOID TRACE ANALYSIS

	Concentration [% w/w]	Expanded uncertainty [% w/w]	LOQ [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b> - Cannabidivarin	0.077	0.018	0.00030	
<b>CBDA</b> - Cannabidiolic acid	0.0090	0.0021	0.00030	
<b>CBGA</b> - Cannabigerolic acid	0.0065	0.0019	0.00030	
<b>CBG</b> - Cannabigerol	0.074	0.022	0.00030	
<b>CBD</b> - Cannabidiol	5.39	0.27	0.03000	
<b>THCV</b> - Tetrahydrocannabivarin	0.0173	0.0036	0.00030	
<b>CBN</b> - Cannabinol	0.0406	0.0089	0.00030	
<b>Δ<sup>9</sup>-THC</b> - Δ-9-Tetrahydrocannabinol	0.136	0.023	0.00030	
<b>Δ<sup>8</sup>-THC</b> - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	0.00030	
<b>CBL</b> - Cannabicyclol	0.0195	0.0043	0.00030	
<b>CBC</b> - Cannabichromene	0.129	0.022	0.00030	
<b>Δ<sup>9</sup>-THCA</b> - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	0.00030	
<b>CBE</b> - Cannabielsoin	0.092 #	0.026	0.00030	
<b>CBNV</b> - Cannabivarin	0.00085 #	0.00019	0.00030	
<b>CBCA</b> - Cannabichromenic acid	< LOQ #	n/a	0.00030	
<b>CBT</b> - Cannabicitran	0.0229 #	0.0050	0.00030	

Units and abbreviations: % w/w = weight percent, LOQ = the limit of quantitation, ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor  $k = 2$ , corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

28/10/2022

Approved by:

mag. Marko Dragan  
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate